Intra-Cellular Therapies, Inc. (NASDAQ: ITCI – Get a rating) Chief Financial Officer Lawrence J. Hineline sold 65,164 shares of the company in a trade on Wednesday, September 21. The shares were sold at an average price of $45.63, for a total transaction of $2,973,433.32. The transaction was disclosed in a document filed with the SEC, accessible via this hyperlink.
Price performance of intra-cellular therapies
NASDAQ: ITCI was down $2.20 on Friday, hitting $43.51. The stock had a trading volume of 912,534 shares, compared to an average volume of 940,529. The company has a market capitalization of $4.11 billion, a price-earnings ratio of -11.76 and a beta of 1.19. The company’s fifty-day moving average is $52.24 and its two-hundred-day moving average is $55.50. Intra-Cellular Therapies, Inc. has a 12-month low of $34.43 and a 12-month high of $66.00.
Intra-Cellular Therapies (NASDAQ:ITCI – Get a rating) last reported its quarterly earnings data on Tuesday, August 9. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.13). Intra-Cellular Therapies had a negative return on equity of 53.13% and a negative net margin of 232.11%. The company posted revenue of $55.58 million for the quarter, compared to $48.62 million expected by analysts. In the same quarter of the previous year, the company made ($0.85) earnings per share. The company’s revenue increased 177.2% year over year. As a group, research analysts expect Intra-Cellular Therapies, Inc. to post earnings per share of -3.36 for the current fiscal year.
A Wall Street analyst gives his opinion
Several stock analysts have recently weighed in on ITCI shares. Needham & Company LLC raised its price target on Intra-Cellular Therapies shares from $65.00 to $67.00 and gave the stock a “buy” rating in a Wednesday, August 10 research note . Goldman Sachs Group cut shares of Intra-Cellular Therapies from a ‘buy’ rating to a ‘neutral’ rating and lowered its price target for the company from $64.00 to $49.00 in a report research on Monday August 22. UBS Group began covering the actions of intra-cellular therapies in a research report on Monday, June 13. They set a “buy” rating and a price target of $75.00 for the company. Finally, Mizuho lowered its price target on shares of Intra-Cellular Therapies from $75.00 to $72.00 and set a “buy” rating for the company in a Thursday, August 11 report. One equity research analyst gave the stock a sell rating, two gave the stock a hold rating and six gave the stock a buy rating. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $60.88.
Institutional trade in intra-cellular therapies
Hedge funds have recently changed their positions in the stock. US Bancorp DE increased its stake in Intra-Cellular Therapies by 93.8% during the second quarter. US Bancorp DE now owns 496 shares of the biopharmaceutical company worth $28,000 after buying 240 more shares in the last quarter. Assetmark Inc. increased its holdings in intracellular therapies by 410.0% during the second quarter. Assetmark Inc. now owns 510 shares of the biopharmaceutical company worth $29,000 after acquiring an additional 410 shares during the period. Exchange Traded Concepts LLC acquired a new position in intracellular therapies during the first quarter worth approximately $33,000. Northern Oak Wealth Management Inc. acquired a new position in intracellular therapies during the second quarter worth approximately $51,000. Finally, FourThought Financial LLC bought a new position in intra-cellular therapies in Q1 worth approximately $54,000. Institutional investors and hedge funds hold 85.48% of the company’s shares.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, is developing novel drugs for the treatment of neuropsychiatric and neurological diseases by targeting intracellular signaling mechanisms in the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider intracellular therapies, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes higher…and intracellular therapies weren’t on the list.
While Intra-Cellular Therapies currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here